为了快速识别人体组织中的各种癌细胞，开发了一种由光学波形形成的独特的菱形空心光子晶体光纤（PCF）并进行了计算研究。在这项调查中，我们发现了最常见的癌症，例如 HeLa 衍生的宫颈癌。由于正常细胞和癌细胞的折射率 (RI) 不同，因此可以使用此信息评估其他重要的光学特性。通过使用有限元法（一种用于求解联立方程的计算工具），使用 COMSOL-Multiphysics 软件检查所建议的癌细胞传感器的定义特征。此外，使用严格的网格部件来保持最高水平的建模真实感。在2.4太赫兹频率下，PCF探测器对宫颈癌细胞和宫颈正常细胞的相对灵敏度约为97.51%和96.29%，限制损失分别为6.1×10 -09db/m和4.39×10-07db/m。基于这些传统的性能指标值，简单的 PCF 结构为使用连续制造技术提供了广泛的应用机会。该生物传感器利用癌细胞独特的折射特性，为宫颈癌的早期识别提供高度准确且可靠的方法。这有可能显着改变宫颈癌筛查的过程。这种新颖的方法提高了检测和识别某些病症的能力，从而提高了早期治疗的诊断能力，并为患者带来更好的结果。© 2024。作者获得 Springer Science Business Media, LLC（Springer 旗下公司）的独家许可自然。

In order to rapidly identify various species of cancer cells in the tissues of person, a unique diamond shaped hollow-core photonic crystal fiber (PCF)-formed by optical waveform is developed and computationally studied. In this investigation, we found the most prevalent cancers, such as HeLa-derived cervical carcinoma. Since normal and cancer cells differ in their refractive indices (RIs), other significant optical properties can be assessed using this information. With the use of the finite element method, a computational tool for solving simultaneous equations, the defining characteristics the suggested cancer cell sensor are examined using COMSOL-Multiphysics software. Additionally, strict mesh parts are used to preserve the utmost level of modeling realism. At 2.4 THz, the PCF detector attains a Relative Sensitivity of around 97.51% and 96.29%, Confinement Loss of 6.1 × 10 -09db/m and 4.39 × 10-07db/m with respect to cervical carcinoma cell and cervical normal cell. The straightforward PCF structure provides a wide chance of application using the continuing fabrication technique, based on these conventional values of performance indices. This biosensor utilizes the distinctive refractive characteristics of cancer cells, providing a highly accurate and dependable approach for the early identification of cervical cancer. This has the potential to significantly transform the process of cervical cancer screening. The novel method boosts the ability to detect and identify certain conditions, leading to increased diagnostic capabilities for early treatment and better results for patients.© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.